IRVINE, Calif., May 21, 2017 -- Pain Management Center of Irvine recently released information on the superiority of SurForce® compared to prolotherapy or PRP. Unlike the alternatives, which take hours per appointment, SurForce® only requires 15 minutes per session. SurForce® is also painless, while the other two options can be painful. The SurForce® treatments also promote healing rather than only managing pain.
Prolotherapy is an older treatment method that involves injecting dextrose into painful tissues to intentionally cause an inflammatory response. The underlying belief is that it will cause the body to speed healing in the inflamed area as well as the injured part. In practice, however, it is used to manage pain instead of to regenerate tissue. Unfortunately, the inflammation it brings on actually causes pain for the duration of the treatments.
Platelet Rich Plasma (PRP) is a stem cell therapy made up of blood, bone marrow, and fat (adipose) tissue. Getting these ingredients involves sucking bone marrow and fat out of the patient's body, and this is said to be a very painful process. It is even worse for older patients since they have fewer viable stem cells and need to donate more tissue to make up for this.
"It is clear that these older methods each have significant shortcomings. This is why we decided to implement the SurForce® system instead. SurForce® combines amniotic membrane tissue, biological scaffolding, and hyaluronic acid to provide a strong healing boost to painful areas via the addition of stem cells. This not only relieves pain, but allows the body to heal faster. Even better, this treatment is delivered by a painless injection," explained Dr. Rick Letts of Pain Management Center of Irvine.
Many people have questions when they learn that amniotic membrane is part of the SurForce® treatment. Specifically, they want to know where it comes from. There is no need for concern over this aspect of SurForce®. The FDA regulated amniotic membrane is voluntarily donated by women who have had cesarean deliveries.
Like many other healing treatments, SurForce® takes several weeks to fully implant in a patient, which is when the most noticeable improvement to their condition can be observed. Therefore, patients are advised to stick to light activity for the first few weeks. This ensures that everything will heal properly and prevent further injury during the course of treatment.
About Pain Management Center of Irvine
The Center offers a wide variety of pain management treatments, ranging from advanced stem cell therapy all the way to traditional healing methods like acupuncture and cupping. It serves the area of Irvine, CA.
To learn more about SurForce®, visit the Pain Management Center of Irvine’s website at http://chirocenterofirvine.com/.
Pain Management Center of Irvine 4902 Irvine Center Dr. #201 Irvine, CA 92604 (949) 857-4712


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



